<DOC>
	<DOC>NCT00919607</DOC>
	<brief_summary>The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .</brief_summary>
	<brief_title>Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Men and women aged 18 through 60 years inclusive Schizophrenia diagnosis Body Mass Index (BMI) 2027 kg/m2 (inclusive) Provision of written informed consent before initiation of any study AIDS &amp; hepatitis B History of seizure disorder History of episodic,idiopathic orthostatic hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>quetiapine fumarate(SEROQUEL) extended-release(XR) China PK Study</keyword>
	<keyword>pharmacokinetics parameters</keyword>
</DOC>